Clearbridge Health Limited, a key player in Singapore’s healthcare sector, has announced a significant development that could have major implications for its shareholders and potential investors. The company has received an in-principle approval from the Singapore Exchange Securities Trading Limited (SGX-ST) for the listing and quotation of 309,500,000 new ordinary shares on the Catalist board. This announcement follows the company’s earlier disclosure on December 19, 2024, regarding its proposed placement of these shares.

Key Highlights from the Announcement

• Approval Secured: As of January 8, 2025, Clearbridge Health has obtained the Listing and Quotation Notice (LQN) from SGX-ST for the Proposed Placement of 309.5 million new shares.
• Placement Deadline: The Subscription Shares must be placed out within seven market days from the LQN’s date.
• Conditional Approval: The LQN is contingent on the company’s compliance with SGX-ST’s listing requirements.
• No Merits Assessed: SGX-ST’s approval does not reflect the merits of the Proposed Placement, the Subscription Shares, or the company and its securities.

What Shareholders Need to Know

For shareholders and potential investors, this development can be significant for several reasons:

• The issuance of 309.5 million new shares represents a substantial increase in the company’s share capital, which could lead to dilution for existing shareholders.
• The capital raised from this placement, depending on its utilization, could strengthen Clearbridge Health’s financial position and fuel growth initiatives.
• The company has committed to keeping shareholders informed about material developments regarding the Proposed Placement.

However, shareholders are urged to exercise caution when dealing in the company’s securities, as the LQN does not guarantee the success of the Proposed Placement or its impact on the company’s financial health and stock value. Any uncertainties or missteps in execution might affect investor confidence and share prices.

Next Steps

Clearbridge Health has pledged to release updates and announcements as appropriate to keep its shareholders informed about the Proposed Placement’s progress. Investors are advised to monitor these updates closely and consult professional advisers if needed.